Investment & Fund Management
with backing from the European Investment
Full Credential Description
KiOmed Pharma, a Belgian spin-off from the University of Liège, specializes in advanced medical devices and is currently developing a new medical gel based on chitosan. This innovative gel is intended for intra-articular injections to alleviate arthritis pain, aiming to restore the natural properties of affected joints and delay the need for replacement surgery. The CEO, Houtaï Choumane, highlighted that existing treatments have limitations in effectiveness, and their product is designed to be injected only once every six months, significantly improving patient compliance compared to current options.
As the project progressed into clinical trials, KiOmed faced challenges in expanding its team and financing further research and development. To address these needs, Houtaï secured a loan guaranteed by the Walloon regional guarantee institution Sowalfin, with backing from the European Investment Fund (EIF) under the Investment Plan for Europe. This support enabled KiOmed to hire ten additional employees, facilitating the advancement of their innovative solutions to combat long-standing health issues. The investment not only bolstered the company's workforce but also accelerated the development of their promising medical technology.